Theratechnologies Inc (TSE:TH) Director Luc Tanguay bought 2,300 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of C$6.64 per share, for a total transaction of C$15,272.00.
Theratechnologies Inc (TSE:TH) opened at C$6.60 on Monday. Theratechnologies Inc has a 1 year low of C$2.61 and a 1 year high of C$8.72.
A number of research analysts have issued reports on TH shares. National Bank Financial boosted their price objective on shares of Theratechnologies from C$9.25 to C$9.75 and gave the company an “outperform” rating in a research report on Thursday, October 5th. Scotiabank reduced their price objective on shares of Theratechnologies from C$10.00 to C$9.25 and set an “outperform” rating on the stock in a research report on Friday, October 6th.
Theratechnologies Inc is a specialty pharmaceutical company. The Company addresses medical needs to promote healthy living among human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.